Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy

Therapeutic Advances in Medical Oncology

Volumn 7, Issue 5, 2015, Pages 274-290

  Liao, Bin Chi ^a   Lin, Chia Chi ^a   Shih, Jin Yuan ^a   Yang, James Chih Hsin ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Alectinib; Ceritinib; Crizotinib; EML4 ALK rearrangement; Heat shock protein 90 inhibitor; Non small cell lung cancer

Indexed keywords

2 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 4 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO] 1,3,5 TRIAZINE; 6 AMINO 5 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] N [4 (4 METHYL 1 PIPERAZINYLCARBONYL)PHENYL] 3 PYRIDAZINECARBOXAMIDE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CEP 37440; CERITINIB; CRIZOTINIB; ENTRECTINIB; GANETESPIB; LUMINESPIB; ONALESPIB; PF 06463922; RETASPIMYCIN; TSR 011; UNCLASSIFIED DRUG; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE;

ADVANCED CANCER; CANCER RESISTANCE; CANCER THERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; HUMAN; JAPAN; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 84940190644     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834015590593     Document Type: Review

References (123)

1. Acquaviva J. Smith D. Sang J. Friedland J. He S. Sequeira M. et al (2012) Targeting KRAS-mutant non–small cell lung cancer with the Hsp 90 inhibitor ganetespib. Mol Cancer Ther 11: 2633–2643.
2. Ardini E. Menichincheri M. Banfi P. Saccardo M. Rusconi L. Avanzi N. et al (2011) Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to xalkori. Mol Cancer Ther 10: A232.
3. Ardini E. Menichincheri M. de Ponti C. Amboldi N. Saccardo M. Texido G. et al (2009) Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models. Mol Cancer Ther 8: A243.
4. Bergethon K. Shaw A. Ignatius Ou S. Katayama R. Lovly C. McDonald N. et al (2012) ROS 1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30: 863–870.
5. Camidge D. Bang Y. Kwak E. Iafrate A. Varella-Garcia M. Fox S. et al (2012) Activity and safety of crizotinib in Patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13: 1011–1019.
6. Camidge D. Bazhenova L. Salgia R. Weiss G. Langer C. Shaw A. et al (2013) First-in-human dose-finding study of the ALK / EGFR inhibitor AP 26113 in patients with advanced malignancies: updated results. ASCO Meeting Abstracts 31: abstract 8031.
7. Camidge D. Kono S. Lu X. Okuyama S. Barón A. Oton A. et al (2011) Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 6: 774–780.
8. Cheng M. Quail M. Gingrich D. Ott G. Lu L. Wan W. et al (2012) CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther 11: 670–679.
9. Choi Y. Soda M. Yamashita Y. Ueno T. Takashima J. Nakajima T. et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363: 1734–1739.
10. Conklin C. Craddock K. Have C. Laskin J. Couture C. Ionescu D. (2013) Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non–small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 8: 45–51.
11. Costa D. Kobayashi S. (2012) Acquired resistance to the ALK Inhibitor crizotinib in the absence of an ALK mutation. J Thorac Oncol 7: 623–625.
12. Costa D. Shaw A. Ou S. Solomon B. et al. (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases. J Clin Oncol. 26 January 2015. [Epub ahead of print]
13. Cui J. Tran-Dubé M. Shen H. Nambu M. Kung P. Pairish M. et al (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54: 6342–6363.
14. de Braud F. Pilla L. Niger M. Damian S. Bardazza B. Martinetti A. et al (2014 a) Phase 1 open label, dose escalation study of RXDX101, an oral Pan-TRK, ROS1, and ALK Inhibitor, in patients with advanced solid tumors with relevant molecular alterations. ASCO Meeting Abstracts 32: abstract 2502.
15. de Braud F. Pilla L. Niger M. Damian S. Bardazza B. Martinetti A. et al (2014 b) 448PDRXDX-101, an oral pan-TRK, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. Ann Oncol 25: iv148–iv149.
16. Doebele R. Pilling A. Aisner D. Kutateladze T. Le A. Weickhardt A. et al (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non–small cell lung cancer. Clin Cancer Res 18: 1472–1482.
17. Eccles S. Massey A. Raynaud F. Sharp S. Box G. Valenti M. et al (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68: 2850–2860.
18. Felip E. Carcereny E. Barlesi F. Gandhi L. Sequist L. Kim S. et al (2012) Phase II activity of the Hsp 90 Inhibitor AUY 922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer (NSCLC). Ann Oncol 23: ix152–ix174.
19. Friboulet L. Li N. Katayama R. Lee C. Gainor J. Crystal A. et al (2014) The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer. Cancer Discov 4: 662–673.
20. Gadgeel S. Gandhi L. Riely G. Chiappori A. West H. Azada M. et al (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1 / 2 study. Lancet Oncol 15: 1119–1128.
21. Gainor J. Ou S. Logan J. Borges L. Shaw A. (2013 a) The central nervous system as a sanctuary site in ALK-positive non–small-cell lung cancer. J Thorac Oncol 8: 1570–1573.
22. Gainor J. Shaw A. (2013) Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 31: 3987–3996.
23. Gainor J. Varghese A. Ou S. Kabraji S. Awad M. Katayama R. et al (2013 b) ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non–small cell lung cancer. Clin Cancer Res 19: 4273–4281.
24. Galkin A. Melnick J. Kim S. Hood T. Li N. Li L. et al (2007) Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A 104: 270–275.
25. Gandhi L. Drappatz J. Ramaiya N. Otterson G. (2013) High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non–small-cell lung cancer. J Thorac Oncol 8: e3–e5.
26. Garon E. Finn R. Hamidi H. Dering J. Pitts S. Kamranpour N. et al (2013) The Hsp 90 inhibitor NVP-AUY922 potently inhibits non–small cell lung cancer growth. Mol Cancer Ther 12: 890–900.
27. Gettinger S. Bazhenova L. Salgia R. Langer C. Gold K. Rosell R. et al (2014 a) 1292PALK inhibitor AP 26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC): updated efficacy and safety data. Ann Oncol 25: iv455.
28. Gettinger S. Bazhenova L. Salgia R. Langer C. Gold K. Rosell R. et al (2014 b) Updated efficacy and safety of the ALK inhibitor AP 26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 32: abstract 8047.
29. Graham B. Curry J. Smyth T. Fazal L. Feltell R. Harada I. et al (2012) The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer. Cancer Sci 103: 522–527.
30. Hanna N. Shepherd F. Fossella F. Pereira J. de Marinis F. von Pawel J. et al (2004) Randomised phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589–1597.
31. Horn L. Infante J. Blumenschein G. Wakelee H. Arkenau H. Dukart G. et al (2014) A Phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. ASCO Meeting Abstracts 32: abstract 8030.
32. Huang D. Kim D. Kotsakis A. Deng S. Lira P. Ho S. et al (2013) Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics 102: 157–162.
33. Inamura K. Takeuchi K. Togashi Y. Hatano S. Ninomiya H. Motoi N. et al (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22: 508–515.
34. Inamura K. Takeuchi K. Togashi Y. Nomura K. Ninomiya H. Okui M. et al (2008) EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3: 13–17.
35. Johnson T. Bailey S. Burke B. Collins M. Cui J. Deal J. et al (2013) Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations. Mol Cancer Ther 12: PR10.
36. Johnson T. Richardson P. Bailey S. Brooun A. Burke B. Collins M. et al (2014) Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem 57: 4720–4744.
37. Jokoji R. Yamasaki T. Minami S. Komuta K. Sakamaki Y. Takeuchi K. et al (2010) Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 63: 1066–1070.
38. Katayama R. Friboulet L. Koike S. Lockerman E. Khan T. Gainor J. et al (2014) Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 20: 5686–5696.
39. Katayama R. Shaw A. Khan T. Mino-Kenudson M. Solomon B. Halmos B. et al (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4: 120ra117.
40. Kim D. Ahn M. Shi Y. de Pas T. Yang P. Riely G. et al (2012) Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 30: abstract 7533.
41. Kim D. Mehra R. Tan D. Felip E. Chow L. Camidge D. et al (2014) Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial. ASCO Meeting Abstracts 32: abstract 8003.
42. Kim H. Kim W. Choi Y. Choi C. Rho J. Lee J. (2013 a) Epithelial-mesenchymal transition leads to crizotinib resistance in H 2228 lung cancer cells with EML4-ALK translocation. Mol Oncol 7: 1093–1102.
43. Kim S. Kim T. Kim D. Go H. Keam B. Lee S. et al (2013 b) Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol 8: 415–422.
44. Kim Y. Ozasa H. Nagai H. Sakamori Y. Yoshida H. Yagi Y. et al (2013 c) High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol 8: e85–e86.
45. Kinoshita K. Asoh K. Furuichi N. Ito T. Kawada H. Hara S. et al (2012) Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem 20: 1271–1280.
46. Kobayashi Y. Sakao Y. Ito S. Park J. Kuroda H. Sakakura N. et al (2013) Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies. J Thorac Oncol 8: e75–e78.
47. Kodama T. Hasegawa M. Takanashi K. Sakurai Y. Kondoh O. Sakamoto H. (2014 a) Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74: 1023–1028.
48. Kodama T. Tsukaguchi T. Yoshida M. Kondoh O. Sakamoto H. (2014 b) Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 351: 215–221.
49. Koivunen J. Mermel C. Zejnullahu K. Murphy C. Lifshits E. Holmes A. et al (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275–4283.
50. Kwak E. Bang Y. Camidge D. Shaw A. Solomon B. Maki R. et al (2010) Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N Engl J Med 363: 1693–1703.
51. Lee J. Kim T. Lee S. Kim D. Kim S. Jeon Y. et al (2011) Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 6: 1474–1480.
52. Lin Y. Wang Y. Yang J. Yu C. Wu S. Shih J. et al (2014) Development of renal cysts after crizotinib treatment in advanced ALK-positive non–small-cell lung cancer. J Thorac Oncol 9: 1720–1725.
53. Lovly C. Heuckmann J. de Stanchina E. Chen H. Thomas R. Liang C. et al (2011) Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 71: 4920–4931.
54. Lovly C. McDonald N. Chen H. Ortiz-Cuaran S. Heukamp L. Yan Y. et al (2014) Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 20: 1027–1034.
55. Lovly C. Pao W. (2012) Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med 4: 120ps2.
56. Maemondo M. Inoue A. Kobayashi K. Sugawara S. Oizumi S. Isobe H. et al (2010) Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380–2388.
57. Maillet D. Martel-Lafay I. Arpin D. Pérol M. (2013) Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. J Thorac Oncol 8: e30–e31.
58. Maitland M. Ou S. Tolcher A. Lorusso P. Bahceci E. Ball H. et al. (2014) Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design. ASCO Meeting Abstracts 32: abstract 2624.
59. Marsilje T. Pei W. Chen B. Lu W. Uno T. Jin Y. et al (2013) Synthesis, structure–activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 56: 5675–5690.
60. Mok T. Wu Y. Thongprasert S. Yang C. Chu D. Saijo N. et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957.
61. Mori M. Ueno Y. Konagai S. Fushiki H. Shimada I. Kondoh Y. et al (2014) The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP 3026 induces tumor regression and prolongs survival in non–small cell lung cancer model mice. Mol Cancer Ther 13: 329–340.
62. Nakagawa K. Hida T. Seto T. Satouchi M. Nishio M. Hotta K. et al (2014) Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study. ASCO Meeting Abstracts 32: abstract 8103.
63. Neckers L. Workman P. (2012) Hsp 90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18: 64–76.
64. Nogova L. Mattonet C. Scheffler M. Michels S. Bos M. Heukamp L. et al (2014) 1238PTRY - a phase II study to evaluate safety and efficacy of combined trastuzumab and the Hsp 90 inhibitor AUY 922 in advanced non-small-cell lung cancer (NSCLC) with HER 2 overexpression or amplification or mutation. Ann Oncol 25(Suppl. 4): iv433.
65. Normant E. Paez G. West K. Lim A. Slocum K. Tunkey C. et al (2011) The Hsp 90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 30: 2581–2586.
66. Ou S. Azada M. Dy J. Stiber J. (2011 a) Asymptomatic profound sinus bradycardia (heart rate ⩽45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol 6: 2135–2137.
67. Ou S. Jänne P. Bartlett C. Tang Y. Kim D. Otterson G. et al (2014 a) Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 25: 415–422.
68. Ou S. Azada M. Hsiang D. Herman J. Kain T. Siwak-Tapp C. et al. (2014 b) Nextgeneration sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 9: 549–553.
69. Ou S. Kwak E. Siwak-Tapp C. Dy J. Bergethon K. Clark J. et al (2011 b) Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6: 942–946.
70. Ou S. Tong W. Azada M. Siwak-Tapp C. Dy J. Stiber J. (2013) Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer 119: 1969–1975.
71. Park H. Lee J. Kim D. Kulig K. Kim T. Lee S. et al (2012) Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 77: 288–292.
72. Pillai R. Ramalingam S. (2014) Heat shock protein 90 inhibitors in non-small-cell lung cancer. Curr Opin Oncol 26: 159–164.
73. Politi K. Gettinger S. (2014) Perfect alkemy: optimizing the use of ALK-directed therapies in lung cancer. Clin Cancer Res 20: 5576–5578.
74. Proia D. Sang J. He S. Smith D. Sequeira M. Zhang C. et al (2012) Synergistic activity of the Hsp 90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs 30: 2201–2209.
75. Ramalingam S. Goss G. Andric Z. Bondarenko I. Zaric B. Ceric T. et al (2013) A randomised study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). ASCO Meeting Abstracts 31: abstract CRA8007.
76. Ramalingam S. Zaric B. Ceric T. Ciuleanu T. Spicer J. Bondarenko I. et al (2014) Galaxy-2 trial (NCT01798485): a randomised phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma. ASCO Meeting Abstracts 32: abstract TPS8118.
77. Rivera V. Wang F. Anjum R. Zhang S. Squillace R. Keats J. et al (2012) AP26113 is a dual ALK / EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLC [AACR abstract 1794]. Cancer Res 72: 1794.
78. Rodig S. Mino-Kenudson M. Dacic S. Yeap B. Shaw A. Barletta J. et al (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15: 5216–5223.
79. Rothenstein J. Letarte N. (2014) Managing treatment–related adverse events associated with ALK inhibitors. Curr Oncol 21: 19–26.
80. Sakamoto H. Tsukaguchi T. Hiroshima S. Kodama T. Kobayashi T. Fukami T. et al (2011) CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19: 679–690.
81. Sang J. Acquaviva J. Friedland J. Smith D. Sequeira M. Zhang C. et al (2013) Targeted inhibition of the molecular chaperone Hsp 90 overcomes ALK inhibitor resistance in non–small cell lung cancer. Cancer Discov 3: 430–443.
82. Sasaki T. Koivunen J. Ogino A. Yanagita M. Nikiforow S. Zheng W. et al (2011) A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 71: 6051–6060.
83. Sasaki T. Okuda K. Zheng W. Butrynski J. Capelletti M. Wang L. et al (2010) The neuroblastoma-associated F1174l ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 70: 10038–10043.
84. Sequist L. Gettinger S. Senzer N. Martins R. Jänne P. Lilenbaum R. et al (2010) Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non–small-cell lung cancer. J Clin Oncol 28: 4953–4960.
85. Sequist L. Yang J. Yamamoto N. O'Byrne K. Hirsh V. Mok T. et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31: 3327–3334.
86. Seto T. Kiura K. Nishio M. Nakagawa K. Maemondo M. Inoue A. et al (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 14: 590–598.
87. Shanthi E. Krishna M. Arunesh G. Venkateswara Reddy K. Sooriya Kumar J. Viswanadhan V. (2014) Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review. Expert Opin Ther Pat 24: 1077–1100.
88. Shaw A. Kim D. Mehra R. Tan D. Felip E. Chow L. et al (2014) Ceritinib in ALK-rearranged non–small-cell lung cancer. N Engl J Med 370: 1189–1197.
89. Shaw A. Kim D. Nakagawa K. Seto T. Crinó L. Ahn M. et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385–2394.
90. Shaw A. Yeap B. Mino-Kenudson M. Digumarthy S. Costa D. Heist R. et al (2009) Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247–4253.
91. Shimamura T. Perera S. Foley K. Sang J. Rodig S. Inoue T. et al (2012) Ganetespib (STA-9090), a nongeldanamycin Hsp 90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non–small cell lung cancer. Clin Cancer Res 18: 4973–4985.
92. Socinski M. Goldman J. El-Hariry I. Koczywas M. Vukovic V. Horn L. et al (2013) A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non–small cell lung cancer. Clin Cancer Res 19: 3068–3077.
93. Soda M. Choi Y. Enomoto M. Takada S. Yamashita Y. Ishikawa S. et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561–566.
94. Soda M. Takada S. Takeuchi K. Choi Y. Enomoto M. Ueno T. et al (2008) A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 105: 19893–19897.
95. Solomon B. Mok T. Kim D. Wu Y. Nakagawa K. Mekhail T. et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371: 2167–2177.
96. Squillace R. Anjum R. Miller D. Vodala S. Moran L. Wang F. et al (2013) AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS 1 fusions [AACR abstract 5655]. Cancer Res 73.
97. Takeda M. Okamoto I. Nakagawa K. (2013) Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 8: 654–657.
98. Takeuchi K. Choi Y. Togashi Y. Soda M. Hatano S. Inamura K. et al (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143–3149.
99. Tamiya A. Okamoto I. Miyazaki M. Shimizu S. Kitaichi M. Nakagawa K. (2013) Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK positive non-small cell lung cancer. J Clin Oncol 31: e15–e17.
100. Tanizaki J. Okamoto I. Okabe T. Sakai K. Tanaka K. Hayashi H. et al (2012) Activation of her family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK–positive non–small cell lung cancer. Clin Cancer Res 18: 6219–6226.
101. Togashi Y. Soda M. Sakata S. Sugawara E. Hatano S. Asaka R. et al (2012) KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PloS ONE 7: e31323.
102. Trepel J. Mollapour M. Giaccone G. Neckers L. (2010) Targeting the dynamic Hsp 90 complex in cancer. Nat Rev Cancer 10: 537–549.
103. Vaishnavi A. Capelletti M. Le A. Kako S. Butaney M. Ercan D. et al (2013) Oncogenic and drug-sensitive NTRK 1 rearrangements in lung cancer. Nat Med 19: 1469–1472.
104. Wang W. Shiao H. Lee C. Fung K. Hsieh H. (2014) Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery. Med Chem Comm 5: 1266–1279.
105. Weickhardt A. Doebele R. Purcell W. Bunn P. Oton A. Rothman M. et al (2013) Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer 119: 2383–2390.
106. Weickhardt A. Rothman M. Salian-Mehta S. Kiseljak-Vassiliades K. Oton A. Doebele R. et al (2012) Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 118: 5302–5309.
107. Weiss G. Sachdev J. Infante J. Mita M. Natale R. Arkenau H. et al (2014) Phase (Ph) 1 / 2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations. ASCO Meeting Abstracts 32: abstract e19005.
108. Whitesell L. Lindquist S. (2005) Hsp90 and the chaperoning of cancer. Nat Rev Cancer 5: 761–772.
109. Wilcoxen K. Brake R. Saffran D. Teffera Y. Choquette D. Whittington D. et al (2012) Characterization of a novel series of potent, selective inhibitors of wild type and mutant / fusion anaplastic lymphoma kinase [AACR abstract 1795]. Cancer Res 72: 1795.
110. Wong D. Leung E. So K. Tam I. Sihoe A. Cheng L. et al (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115: 1723–1733.
111. Woodhead A. Angove H. Carr M. Chessari G. Congreve M. Coyle J. et al (2010) Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp 90 by fragment based drug design. J Med Chem 53: 5956–5969.
112. Wu S. Kuo Y. Chang Y. Shih J. Chen Y. Tsai M. et al (2012) EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 7: 98–104.
113. Yamada T. Takeuchi S. Nakade J. Kita K. Nakagawa T. Nanjo S. et al (2012) Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res 18: 3592–3602.
114. Yamaguchi N. Lucena-Araujo A. Nakayama S. de Figueiredo-Pontes L. Gonzalez D. Yasuda H. et al (2014) Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer 83: 37–43.
115. Yang J. (2013) A selective ALK inhibitor in ALK-rearranged patients. Lancet Oncol 14: 564–565.
116. Yang J. Hirsh V. Schuler M. Yamamoto N. O'Byrne K. Mok T. et al (2013) Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin / pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 31: 3342–3350.
117. Yasuda H. de Figueiredo-Pontes L. Kobayashi S. Costa D. (2012) Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 7: 1086–1090.
118. Yi E. Boland J. Maleszewski J. Roden A. Oliveira A. Aubry M. et al (2011) Correlation of IHC and fish for ALK gene rearrangement in non-small cell lung carcinoma: IHC ccore algorithm for fish. J Thorac Oncol 6: 459–465.
119. Ying W. Du Z. Sun L. Foley K. Proia D. Blackman R. et al (2012) Ganetespib, a unique triazolone-containing Hsp 90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11: 475–484.
120. Zhang S. Wang F. Keats J. Ning Y. Wardwell S. Moran L. et al (2010) AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 [AACR abstract 3623]. Cancer Res 70: LB-298.
121. Zhang S. Wang F. Keats J. Zhu X. Ning Y. Wardwell S. et al (2011) Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 78: 999–1005.
122. Zou H. Engstrom L. Li Q. West Lu M. Tang R. Wang H. et al (2013 a) Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models. Mol Cancer Ther 12: A277.
123. Zou H. Engstrom L. Li Q. West Lu M. Tang R. Wang H. et al (2013 b) Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo. Mol Cancer Ther 12: C253.